Propylamines - Therapeutic use
Research News and Information

Sunday, November 22, 2009

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]

30 Aug 2009 Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

30 Aug 2009 Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric co-morbidity, and approximately 60% have at ... Read more...

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.

30 Aug 2009 OBJECTIVES: To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia. DESIGN: A randomized, double-blind, placebo (PLA)-controlled, parallel-groups study, starting with a ... Read more...

Latest indexed articles for 'Propylamines - Therapeutic use'

These are the very latest articles for this heading:

• [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
• Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. 30 Aug 2009
• Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. 30 Aug 2009
• Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. 30 Jul 2009
• Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. 30 Jun 2009
• Iptakalim: a new or just another KCO? 8 Jun 2009
• Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. 30 May 2009
• Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. 30 May 2009
• Attention-deficit-hyperactivity disorder: an update. 30 May 2009
• The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. 29 Apr 2009
• Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting. 29 Apr 2009
• Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. 29 Apr 2009
• [Drugs for attention deficit hyperactivity disorder] 29 Apr 2009
• A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. 12 Apr 2009
• A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. 5 Apr 2009
• InforMatrix for attention deficit hyperactivity disorder. 30 Mar 2009
• Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. 30 Mar 2009
• Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. 30 Mar 2009
• Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. 27 Feb 2009
• Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. 27 Feb 2009

See a longer list of these articles.

Technical information about 'Propylamines'

Registry Number: 0

Descriptor UI: D011437

Alternative terms: Propylamines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.092.831;

History Note: 66